Physician profile
Rick White Obray
NPI 1316087372
$22,740.60
in general payments reported to CMS, 2019-2025
22 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $705 · 2021: $894 · 2022: $18K · 2023: $458 · 2024: $1,054 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tenon Medical, INC. | $17,234.33 | 2022 | |
| Boston Scientific Corporation | $3,637.58 | 2019-2025 | General - Pain Management, Intracept, Watchman Flx |
| Abbott Laboratories | $403.23 | 2019-2025 | Proclaim |
| Relievant Medsystems, INC. | $302.45 | 2019-2023 | Intracept |
| Nevro Corp. | $256.49 | 2019-2021 | |
| Abbvie INC. | $171.75 | 2022-2025 | |
| Stryker Corporation | $91.66 | 2019-2025 | Optablate |
| Vertiflex, INC. | $82.96 | 2019 | |
| Medtronic, INC. | $78.49 | 2021-2023 | Intellis Adaptivestim |
| Allergan, INC. | $74.34 | 2019-2020 | |
| Lundbeck LLC | $67.92 | 2021-2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $55.88 | 2019-2024 | Xtampza, Belbuca |
| Grt US Holding, INC. | $42.05 | 2022 | |
| Spr Therapeutics, INC | $37.08 | 2024 | Sprint Pns System |
| Bioventus LLC | $31.65 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.94 | 2019-2024 | |
| Depuy Synthes Sales INC. | $30.51 | 2022 | |
| Nalu Medical, INC. | $28.97 | 2024 | Nalu Neurostimulation System |
| Argenx US, INC. | $22.98 | 2024 | Vyvgart Hytrulo |
| Genentech USA, INC. | $20.53 | 2022 | |
| Medtronic USA, INC. | $19.74 | 2019 | |
| Redhill Biopharma INC. | $19.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$36,050.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Obray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.